ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1365	National Cancer Institute	Html	en	Treatment-Related Nausea and Vomiting (PDQ®)–Health Professional Version	Expert-reviewed information summary about nausea and vomiting as complications of cancer or its treatment. Approaches to the management of nausea and vomiting are discussed.	Navari RM 0.607101 emetogenic cancer chemotherapy 0.63983 Eur J Cancer 0.609061 delayed chemotherapy-induced nausea 0.625115 prevention 0.607994 vomiting 0.735606 moderately emetogenic cancer 0.588642 Hesketh PJ 0.626918 chemotherapy-induced nausea 0.995758 patients 0.657649 postchemotherapy nausea 0.593584 Ann Oncol 0.583271 future chemotherapy cycles 0.584523 cancer chemotherapy 0.674463 postchemotherapy nausea interrelate 0.583875 Cancer Treat Rep 0.590867 receptor antagonist 0.645678 et al. 0.731812 multiday chemotherapy regimen. 0.581142 study 0.614153 3-day chemotherapy regimens 0.58215 emetogenic chemotherapy-induced nausea 0.655987 high-dose cisplatin chemotherapy 0.594488 highly emetogenic chemotherapy 0.717945	cisplatin chemotherapy 0.641758 delayed cisplatin-induced nausea 0.593234 PUBMED Abstract 0.729569 moderately emetogenic chemotherapy 0.836636 Support Care Cancer 0.895503 emetogenic cisplatin-based chemotherapy 0.601411 emetogenic multi-day chemotherapy 0.600149 Patients Receiving Chemotherapy 0.603022 lung cancer chemotherapy 0.587479 multiday chemotherapy 0.602924 dexamethasone 0.645924 Abstract 0.798738 cisplatin-induced emesis 0.607512 Clin Oncol 0.771609 multiday chemotherapy regimen 0.588792 chemotherapy regimen 0.594004 multiple-day cisplatin chemotherapy 0.590292 antiemetic therapy 0.590387 emetogenic multiple-day chemotherapy 0.598957 antiemetic efficacy 0.593069 acute chemotherapy-induced nausea 0.663254 breakthrough chemotherapy-induced nausea 0.630049 acute nausea 0.588031 cisplatin combination chemotherapy 0.606904	CLICK HERE
1588	National Cancer Institute	Html	en	Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of childhood soft tissue sarcomas.	Plexiform fibrohistiocytic tumor 0.280012 malignant tumor cells 0.307621 cancer treatment 0.290865 soft tissue cell 0.275637 rare tumor 0.289328 Inflammatory myofibroblastic tumor 0.282045 childhood soft tissue 0.441268 cell tumor 0.287204 body 0.349975 type 0.32132 PDQ cancer information 0.285649 children 0.277658 clinical trials 0.413146 clinical trial 0.299958 clear cell sarcoma 0.298146 Malignant triton tumor 0.279981 blood vessels 0.296075 smooth muscle tumor 0.277296 lymph nodes 0.29136 radiation therapy 0.449797 soft tissue sarcoma 0.971932 cartilage tumor 0.284625 treatment 0.443484 synovial sarcoma 0.284633	Primitive neuroectodermal tumor 0.276261 nerve sheath tumor 0.323482 chromosome switches places 0.389422 cancer cells 0.417787 tumor cells 0.415668 tumor suppressor gene 0.277153 genetic change 0.398935 soft tissue sarcomas 0.289965 /extraskeletal Ewing tumor 0.27615 fibrous tissue tumor 0.342556 tissue sarcoma cells 0.300511 primary tumor 0.287542 metastatic tumor 0.275814 following types 0.304501 soft tissue tumors 0.283665 PDQ summary 0.323186 tumors 0.289287 tumor 0.552574 Tissue Sarcoma Treatment 0.342732 certain genetic change 0.378247 cancer 0.496155 information 0.290056 Adult Soft Tissue 0.29745 fast-growing tumor 0.287416	CLICK HERE
1642	National Cancer Institute	Html	en	714-X (PDQ®)–Patient Version	714-X is made by mixing chemicals with camphor, a natural substance that comes from the wood and bark of the camphor tree. Read about the theory behind using 714-X and its current use in cancer patients.	peer-reviewed scientific journals 0.537641 treatment 0.534968 cancer treatment 0.501509 cancer prevention 0.385702 Information Service 1-800-4-CANCER 0.351897 Complementary Therapies Editorial 0.514523 United States 0.392202 Cancer Information Specialist 0.412867 Drug Administration 0.382831 NCI Best Case 0.355021 Cancer Information Service 0.561203 PDQ cancer information 0.744788 Cancer Complementary 0.449411 CAM therapies 0.422313 treatment clinical trials 0.37249 National Cancer Institute 0.876336 clinical trials 0.717035 alternative medicine 0.550954 health care 0.367057 scientific journals 0.644656 cancer information summary 0.608674 alternative cancer therapies 0.435258 Federal Trade Commission 0.400026 National Institutes 0.384082	clinical trial 0.420566 National Center 0.380596 CAM cancer research 0.409541 new treatment 0.361031 breast cancer prevention 0.380639 PDQ 714-X 0.397489 PDQ summaries 0.352729 cancer patients 0.471011 Cancer Care page 0.383195 latest published information 0.365664 NCI’s PDQ 0.390788 PDQ summary 0.383221 Integrative Health 0.378723 NCI PDQ cancer 0.513504 cancer information database 0.431786 alternative therapies 0.488998 cancer information summaries 0.432385 Therapies Editorial Board 0.457631 cancer 0.995087 research studies 0.395284 714-X 0.480793 fight cancer cells 0.39917 PDQ Integrative 0.349747	CLICK HERE
1662	National Cancer Institute	Html	en	Childhood Craniopharyngioma Treatment (PDQ®)–Patient Version	Childhood craniopharyngiomas are benign (not cancer) brain tumors found near the pituitary gland. Learn about the signs, tests to diagnose, and treatment (surgery, radiation therapy, chemotherapy, and immunotherapy) of pediatric craniopharyngioma in this expert-reviewed summary.	cancer treatment 0.48468 biologic therapy 0.507196 metastatic brain tumors 0.486695 ongoing clinical trials 0.484802 type 0.50142 PDQ cancer information 0.574719 clinical trial search 0.540589 brain tumors 0.522888 clinical trials 0.951944 Tumors Treatment Overview 0.504097 Pediatric Treatment Editorial 0.495313 cancer information summary 0.533129 External-beam radiation therapy 0.488413 clinical trial 0.688299 treatment clinical trial 0.507181 NCI PDQ cancer 0.492501 radiation therapy 0.972274 Treatment Editorial Board 0.499227 3-dimensional radiation therapy 0.515967 late effects 0.510845 currently used treatment 0.491406 treatment 0.796928 PDQ treatment summary 0.532401 pituitary gland 0.574023 primary brain tumors 0.487104	PDQ Pediatric Treatment 0.494857 childhood craniopharyngioma 0.61051 Benign brain tumors 0.485617 treatment clinical trials 0.53534 National Cancer Institute 0.529019 tumor cells 0.70293 spinal cord 0.496884 tumor treatment 0.551247 optic nerves 0.511248 Childhood Craniopharyngioma Treatment 0.498434 new treatment 0.547603 external radiation therapy 0.527756 brain 0.588207 PDQ summary 0.519792 effects tumor treatment 0.543564 Intracavitary radiation therapy 0.548993 radiation treatment 0.484529 cancer clinical trials 0.558097 tumor 0.711831 treatment options 0.489122 internal radiation therapy 0.557881 cancer 0.593059 standard treatment 0.499934 spinal cord tumors 0.49494	CLICK HERE
1748	National Cancer Institute	Html	en	Formaldehyde and Cancer Risk	A fact sheet that discusses formaldehyde and its possible association with cancer. Includes resources for more information.	U.S. Consumer Product 0.507182 potential health effects 0.45175 nasopharyngeal cancer 0.446819 formaldehyde resins 0.646729 paper product coatings 0.444118 formaldehyde exposure 0.974129 cumulative exposure 0.471192 case-control studies 0.464784 health care professionals 0.44942 laboratory studies 0.445025 building materials 0.458544 highest estimated formaldehyde 0.647871 formaldehyde exposure limit 0.684002 long-term health effects 0.450096 probable human carcinogen 0.44463 formaldehyde exposure levels 0.675206 industrial workers 0.445134 short-term health effects 0.476808 Environmental Protection Agency 0.476151 workplace exposure 0.472844 myeloid leukemia 0.515754 high formaldehyde levels 0.685556 pressed-wood products 0.507453 occupational formaldehyde exposure 0.700409	Product Safety Commission 0.506904 cohort study 0.490021 National Toxicology Program 0.502466 household products 0.463834 British industry workers 0.444394 U.S. Environmental Protection 0.477699 occupational exposure 0.487391 Occupational Safety 0.475151 Emergency Management Agency 0.463126 human carcinogen 0.45778 National Cancer Institute 0.452741 lymphatic systems 0.444691 formaldehyde gas 0.693298 Health Administration 0.456674 NCI cohort 0.451429 NCI case-control study 0.460446 occupational exposure limits 0.480797 Consumer Product Safety 0.50691 NCI industrial cohort 0.459283 lung cancer deaths 0.469841 funeral industry workers 0.472946 lung cancer mortality 0.44468 formaldehyde content 0.617511 prolonged exposure 0.474993	CLICK HERE
1756	National Cancer Institute	Html	en	Alcohol and Cancer Risk	A fact sheet that summarizes the evidence linking alcohol consumption to the risk of various cancers. Includes information about factors that affect the risk of alcohol-associated cancers.	major risk factor 0.235988 esophageal cancer 0.270931 alcohol content 0.304765 alcohol-associated cancer risk 0.218724 alcohol dehydrogenase 0.277499 Heavy alcohol 0.291007 alcohol consumption 0.743494 modestly increased risk 0.222903 colorectal cancer risk 0.261495 alcohol drinkers 0.284781 drinking alcohol 0.321106 alcohol intake 0.325944 ethyl alcohol 0.305684 percent alcohol 0.349039 moderate alcohol drinking 0.333262 Alcohol Abuse 0.303318 studies 0.234236 cancer risk declines 0.219417 alcohol 0.928418 pure alcohol 0.321046	Moderate alcohol intake 0.283695 esophageal squamous cell 0.212278 breast cancer risk 0.237174 S. Alcohol drinking 0.301428 alcohol-related esophageal cancer 0.211228 breast cancer 0.381145 alcohol drinking 0.503002 neck cancers 0.250896 pancreatic cancer risk 0.215956 neck cancer 0.200912 regular alcohol consumption 0.359735 et al 0.397799 cancer risk 0.361737 cancers 0.264383 oral cavity 0.23106 cancer 0.549181 risk 0.431925 liver cancer 0.219113 enzyme drink alcohol 0.313977	CLICK HERE
1923	National Cancer Institute	Html	es	Tratamiento del melanoma (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del melanoma.	almacena agua 0.234953 siguientes procedimientos 0.33648 estadio iv 0.436307 siguientes aspectos 0.242705 CTLA-4.Ampliar Inhibidor 0.229258 genes braf 0.219515 pequeña cantidad 0.22974 siguientes tipos 0.26039 estadios ia 0.227409 ganglio linfático centinela 0.971469 rayos x 0.230817 estadio ib 0.421722 estadio ia 0.418874 enlace drugs approved 0.315654 células t 0.340582 luz solar 0.830082 PD-1.Ampliar Inhibidor 0.228522 vitamina d 0.235166	National Cancer Institute 0.217987 lunar atípico 0.239383 Instituto Nacional 0.232974 estadios iia 0.230643 PDQ Tratamiento 0.658062 melanoma causa efectos 0.315066 antecedentes familiares 0.293778 cabo pruebas 0.278327 estadio iia 0.421244 estadio iic 0.418402 PDQ Exámenes 0.269726 Physician Data Query 0.266129 lápiz mide 0.244567 estadio iii 0.594614 siguientes situaciones 0.233677 panel derecho 0.258009 siguientes pruebas 0.238893 melanoma ocular uveal 0.435674	CLICK HERE
3450	National Cancer Institute	Html	en	Planning the Transition to End-of-Life Care in Advanced Cancer (PDQ®)–Health Professional Version	Expert-reviewed information summary about the preparation needed by health care providers, patients, and families for the transition to end-of-life care in advanced cancer.	lung cancer 0.641373 Cancer patient preferences 0.503664 American Cancer Society 0.471339 palliative care cohort 0.487911 health care providers 0.49452 advance care planning 0.617548 Cancer Care Outcomes 0.545737 Care Outcomes Research 0.519676 colorectal cancer 0.485035 ill hospitalized patients 0.478763 incurable cancer patients 0.49288 breast cancer patients 0.489402 patients 0.763742 cancer patients 0.59867 elderly cancer patients 0.49242 EOL health care 0.473964 incurable cancer 0.495495 decision making 0.513832 metastatic breast cancer 0.474641 et al. 0.585917 care 0.714724 end-of-life care 0.494853 treatment 0.487292 palliative care interventions 0.478305 study 0.52262	Palliative care communication 0.477608 metastatic non-small-cell lung 0.492002 Palliat Support Care 0.474344 palliative care 0.683174 PUBMED Abstract 0.539791 Hosp Palliat Care 0.499255 treatment preferences 0.470843 Support Care Cancer 0.520243 advanced lung cancer 0.489792 advanced colorectal cancer 0.478138 palliative oncology care 0.483778 lung cancer patients 0.527648 early palliative care 0.566869 Intern Med 0.533629 preferences 0.530446 advanced cancer 0.753385 advance directives 0.485421 Abstract 0.690455 Clin Oncol 0.911079 Arch Intern Med 0.488878 medical care 0.489903 randomized controlled trial 0.484267 health care decisions 0.476382 cell lung cancer 0.493742	CLICK HERE
16473	National Cancer Institute	Html	en	Nivolumab Improves Survival for Patients with Recurrent Head and Neck Cancer	A summary of clinical trial results showing that nivolumab (Opdivo®) improved overall survival compared with standard chemotherapy in patients with head and neck squamous cell carcinoma.	platinum-based chemotherapy 0.436007 immune checkpoint inhibitor 0.707571 pembrolizumab block 0.240544 checkpoint inhibitor nivolumab 0.489462 standard therapy group 0.856853 HNSCC tumor growth 0.401684 squamous cells 0.272124 Cancer Therapy Evaluation 0.372634 overall survival 0.94063 broader group 0.255871 poor prognoses 0.250488 median progression-free survival 0.452131 Pittsburgh Medical Center 0.399432 Maura L. Gillison 0.401307 Bristol-Myers Squibb 0.274378 median overall survival 0.493854 patients 0.514717 metastatic HNSCC 0.274208 HNSCC 0.412159 effective second-line therapy 0.394916 Shakun Malik 0.250672 Drug Administration 0.252661 cancer cells 0.262643 treatment-related adverse events 0.35048	Human papillomavirus 0.256631 better treatment 0.263098 unacceptable side effects 0.245803 median follow-up 0.28334 PD-L1—a molecule 0.240638 nivolumab group 0.622355 tumor cells 0.248287 new trial 0.243059 standard chemotherapy 0.417786 Ohio State University 0.396086 median length 0.283635 immune cells 0.271394 salivary glands 0.258435 nasal passages 0.247938 Robert L. Ferris 0.397098 Cancer Institute 0.278018 neck cancer 0.259993 tumor response 0.240293 common adverse events 0.34039 New England Journal 0.393835 oral cavity 0.246829 checkpoint molecule PD-1 0.389662 Earlier studies 0.247274 phase III trial 0.261728	CLICK HERE
16718	National Cancer Institute	Html	es	Estudios clínicos de cáncer en el Centro Clínico de los Institutos Nacionales de la Salud	Información acerca de los estudios clínicos de cáncer en el Centro Clínico de NIH en Bethesda, Maryland.	Centro Clínico 0.997868 investigación clínica 0.340866	Estados Unidos 0.385246 Institutos Nacionales 0.316065	CLICK HERE